KLTO - anewmeds.com Debt to Book Capitalization Ratio

Brandmark of anewmeds.com (KLTO)

The debt-to-capitalization ratio on the balance sheet demonstrates the financial stability of Klotho Neurosciences Inc (KLTO), which is developing Klotho protein-based gene therapy to combat dementia. The value 0.00 represents the current figure for this metric. A compact staff of elite neurologists is retained through a stock option system. Meanwhile, business success depends on the biological cycles of clinical data rather than macroeconomics.

ANEW Medical (KLTO) - Debts to Book Value from 09/18/2024 to 03/11/2026
Original product of Klotho Neurosciences

This ratio determines the proportion of borrowed funds to equity, capturing the enterprise's level of financial risk. Investors utilize the financial stability indicator—debt-to-capitalization—to assess a company's ability to service its obligations. A decrease in this metric confirms reliability, although excessive conservatism may limit growth rates. For Klotho Neurosciences Inc (KLTO), the balance of borrowings is critical when financing preclinical research. Effective management of this leverage provides the resource base for developing innovative drugs against brain aging.

Competitors of Klotho Neurosciences Inc

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|XENE (Xenon Corp) - Debts to Book Value|VKTX (Viking Therapeutics) - Debt to Book Capitalization Ratio|Debts to Book Capitalization SUPN|Debt to Book Capitalization Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|Debt to Book Capitalization Ratio DNLI (Denali)|HRMY: Debt to Book Capitalization Ratio|BHVN - Debts to Book Value|Debt to Book Value Amylyx Pharmaceuticals AMLX|TRVI - Debt to Book Capital|Debts to Book Capitalization Praxis Precision Medicines, Inc. PRAX|AVXL (Anavex) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio CBLL (CeriBell Corp)|Debts to Book Value prothena.com (PRTA)|Alector, Inc. (ALEC) - Debt to Book Value|Debt to Net Assets Ratio ANNX (annexonbio.com)|OMER - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Neurogene Inc NGNE|ACIU (AC Immune Corp) - Debts to Book Capitalization|Voyager Corp (VYGR) - Debts to Book Value|NMRA: Debt to Book Value|SCLX (scilexholding.com) - Debts to Book Capitalization|TVGN - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio ACOG|Cognition Therapeutics - Debt to Book Capitalization Ratio|Debts to Book Value IKT (Inhibikase Pharma)|Debt to Book Capitalization Ratio SAVA|Debts to Net Assets Assertio Holdings ASRT|COYA: Debts to Book Capitalization|VTGN - Debt to Book Value|ovidrx.com - Debts to Book Capitalization|Acumen Pharmaceuticals, Inc (ABOS) - Debts to Net Assets|Debts to Book Capitalization CRVO (CervoMed Inc.)|Debts to Book Value ATHE|Debt to Book Capitalization Ratio Clene Inc. CLNN|Debt to Book Value Ratio pepgen.com (PEPG)|Jupiter Neurosciences Inc - Debts to Book Capitalization|Debt to Book Value Relmada Corp RLMD|ANVS (Annovis Bio, Inc.) - Debts to Book Capitalization|GRCE: Debts to Book Value|Firefly Neuroscience - Debt to Book Capitalization Ratio|Debts to Net Assets NeuroSense Therapeutics Ltd.|RVPH - Debt to Book Value|Debt to Net Assets Ratio MetaVia, Inc.|NRXS (NeurAxis, Inc.) - Debts to Book Capitalization|Debts to Net Assets HSDT (heliusmedical.com)|PASG - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Neuphoria Therapeutics, Inc. NEUP|NERV: Debts to Book Capitalization|ATHA: Debt to Book Value|ADXN: Debt to Book Capitalization Ratio|ALZN (Alzamend Neuro) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Cyclerion Therapeutics Inc.|Debt to Book Capitalization Ratio Protagenic (PTIX)|Debt to Book Value Pasithea Therapeutics|Debt to Book Capital CRGT (cortigent.com)|ATXI: Debt to Book Capitalization Ratio|brainstorm-cell.com - Debts to Book Value|Cara Therapeutics (CARA) - Debt to Book Capitalization Ratio|CHRO - Debt to Book Value Ratio|Debts to Book Capitalization ELYM|Debts to Book Value Intra-Cellular Therapies, Inc.|LBPH (Longboard Pharmaceuticals) - Debt to Book Value|Debts to Book Capitalization MRNS|NKGen Biotech (NKGN) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio NRBO (NeuroBo Pharmaceuticals Inc)|SAGE: Debt to Book Capitalization Ratio|Synaptogenix, Inc - Debts to Book Value|Trevena, Inc. - Debt to Book Capitalization Ratio|VIGL: Debts to Book Capitalization|Anew Medical (WENA) - Debt to Book Capitalization Ratio|CERE (Cerevel Therapeutics Inc) - Debt to Book Capitalization Ratio